Table 3.

IL-1 blocking agents against IL-1β pathway

Drugs	Mechanism of action	Half life	Molecular weight	Comment
Anakinra	Recombinant non-glycosylated form of human IL-1R antagonist	4~6 hours	17.3 kDa	No RCTs available in the treatment of gout
Canakinumab	Fully human anti-IL-1β monoclonal antibody	26 days	145 kDa	EMA approval for treatment of adult patients with frequent gouty arthritis and refractory to standard treatments

IL-1: interleukin-1, RCT: randomized controlled trial, EMA: European Medicines Agency.